Michael X Fu, Maria F Perdomo, Sheila F Lumley, Johan Ringlander, Kai Kean, Kaitlin Reid, Richard Mayne, Oscar Enrique Torres Montaguth, Leysa Forrest, Sarah Buddle, Johannes C Botha, Joakim B Stenbäck, Zachery Dickson, Chris Kent, Haiting Chai, Matthew Byott, Leo Hannolainen, Shannah Secret, George Airey, Klaus Hedman, Monique I Andersson, M Azim Ansari, Eleni Nastouli, Judith Breuer, Philippa C Matthews, Tanya Golubchik, William L Irving, Peter Simmonds, Heli Harvala
This multicentre study investigated the utility of next-generation sequencing (NGS) to detect and generate hepatitis B virus (HBV) genomes in samples of low viral load (from 0.2 to 6207 IU/mL). 23 HBV DNA-positive plasma samples of genotypes A-E and one HBV-negative control sample were assayed blindly via 9 established NGS methods from 6 European laboratories. Methods included untargeted metagenomics, pre-enrichment by probe-capture followed by Illumina sequencing, and HBV-specific PCR pre-amplification followed by sequencing with Nanopore or Illumina. Full HBV genomes were obtained only from samples with viral loads > 1000 IU/mL using probe-capture methods, > 200 IU/mL using PCR-Illumina methods, > 10 IU/mL using PCR-Nanopore methods, and in no samples using metagenomic methods. Contamination was observed in the negative control and samples with very low viral loads in PCR-based methods. Probe-capture and metagenomic methods detected additional viruses not routinely screened in blood donations, including polyomaviruses and herpesviruses; positive results were confirmed by PCR. In conclusion, NGS may delineate whole-genome sequences at low viral loads if supported by a PCR pre-amplification step. Probe-capture methods also reliably detect HBV without pre-amplification but show limited genome coverage for samples with low viral loads; they may additionally detect a wide range of blood-borne viruses.